Search
Botulinum toxin type A
go.drugbank.com/drugs/DB00083ApprovedInvestigationalIn 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. … [A231819,L32569] A popular use for Botox is the treatment of facial wrinkles and lines, however, there are many uses for the botulinum toxin A in the treatment of dystonia, incontinence, migraine, blepharospasm
Categories: Botulinum Toxins, Type ASynonyms: BTX A, BTX-ALorcaserin
go.drugbank.com/drugs/DB04871ApprovedInvestigationalWithdrawnThis decision was based on the results of a clinical trial assessing the risk of heart-related problems that found that patients treated with lorcaserin may have a higher risk of cancer. … In February 2020, the FDA issued a Drug Safety Communication requesting the manufacturer of Belviq (lorcaserin hydrochloride tablets, 10 mg) and Belviq XR (lorcaserin hydrochloride extended-release tablets
Hexobendine
go.drugbank.com/drugs/DB13265ApprovedHexobendine is a medication used to cause vasodilation, to treat several conditions including angina pectoris. … It has not been approved in the United States or the United Kingdom, but has been used widely in Austria and Germany [T478].
Categories: Vasodilators Used in Cardiac DiseasesClascoterone
go.drugbank.com/drugs/DB12499ApprovedInvestigational[A218846] In August 2020, FDA approved clascoterone for the first-in-class topical treatment of acne (acne vulgaris) in male and female patients 12 years and older. … [L15621] Clascoterone is also being investigated as a novel treatment for androgenetic alopecia.[A218766]
Lemborexant
go.drugbank.com/drugs/DB11951ApprovedInvestigationalLemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. … beginning of a new wave of treatment options for patients suffering from insomnia.
Deucravacitinib
go.drugbank.com/drugs/DB16650ApprovedInvestigational[A246938, A246943] This selectivity towards TYK2 may lead to an improved safety profile of deucravacitinib, as nonselective JAK inhibitors are associated with a range of adverse effects such as altered … Deucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor.
Relacorilant
go.drugbank.com/drugs/DB14976ApprovedInvestigationalRelacorilant is a first-in-class, selective glucocorticoid receptor antagonist. … [L56089] Relacorilant was approved by the US FDA on March 25, 2026, for use in combination with [paclitaxel] in patients with certain platinum-resistant cancers.[L56093,L56089]
Oxcarbazepine
go.drugbank.com/drugs/DB00776ApprovedInvestigational[A186011] Compared to other anti-epileptic drugs, which are generally metabolized via the cytochrome P450 system, oxcarbazepine has a reduced propensity for involvement in drug-drug interactions owing … [L8627,L8630,L8633] It is a structural derivative of [carbamazepine][A186101] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exists as a racemate in the blood
Elafibranor
go.drugbank.com/drugs/DB05187ApprovedInvestigationalElafibranor is a dual peroxisome proliferator-activated receptor (PPAR) α and β/δ agonist [A263833] that works to inhibit bile acid synthesis. … [L50773] The drug was also approved by the EMA on September 23, 2024.[L51878]
Brilliant green cation
go.drugbank.com/drugs/DB11279ApprovedVet approvedBrilliant green, or ethanaminium, is a derivative of triarylmethane dye that has been used as a dye to color silk and wool. … Due to its inhibitory actions against Gram positive microorganisms, brilliant green can be found in antiseptic products such as solutions and swabs used to prevent infection.
Mixtures: Kerr 100 Triple Dye Dispos-ACategories: Compounds used in a research, industrial, or household setting